From testing, Delphi-2Ms’ predictions matched or exceeded the accuracy of current models for most diseases. It also proved to ...

For investors, SRRK stock offers a high-probability FDA catalyst, meaningful upside in SMA, and additional optionality in obesity and more.

If you’re wondering how the high court’s lawless sausage got made, we must turn to an obscure line from a long-forgotten 1977 ...

A new study reveals that a gene inherited from Neanderthals reduces muscle activity and may influence athletic performance.

Enhanced’s 3D multi-omics platform delivers genetically validated targets for common diseases, accelerating development and increases rates of success in high-value indicationsFunding from BGF, ...

Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone ...

Some of these fast-growing trees produce sweet, colorful fruits, while others may have a more bitter yield that has other ...

A new Lancet study has raised concerns over the growing burden of chronic diseases among young Indians. Conditions like diabetes, heart disease, and cancer are increasingly contributing to premature ...

As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect ...

The commercial success of existing lipid-lowering medications highlights the enormous market potential for effective ...

Ionis Pharmaceuticals, Inc. ( NASDAQ: IONS) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT ...

Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ...